Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

NeurogesX closes Series C private placement

Executive Summary

NeurogesX (neuropathic pain therapeutics) raised $35mm through the closing of its Series C venture round. New investor Global Life Science Ventures led the placement, and was joined by Diamond Capital Management (representing Dow Employees' Pension Plan and Union Carbide Employees' Pension Plan) and existing investors Alta Partners, Arch Venture Partners, Montreux Equity Partners, Walden International, the Teachers Insurance and Annuity Association, and the University of North Carolina.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Topical Delivery
      • Transdermal
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies